Another potential therapeutic approach is the phosphodiesterase type 5 inhibitor sildenafil, which was recently reported to decrease CXCL10 gene expression and protein secretion in human cardiac myocytes and decrease circulating CXCL10 in subjects with diabetic cardiomyopathy [100]. Here, CXCL10 is linked to diabetic cardiomyopathy.